has been identified as a potential novel PfHDAC. Despite the diversity of structural features, most HDAC inhibitors follow a common pharmacophore model. The traditional pharmacophore model for inhibitors of zinc-dependent HDACs comprises of a cap group that interacts with the entrance surface of the catalytic tunnel, a zinc-binding group (ZBG) that chelates the crucial zinc ion, and a linker that bridges these two components. Figure : HDAC inhibitors approved by the FDA (A) and clinical drug candidate quisinostat (B).